Clinical Trial Search

Primary: Number of Participants With Postoperative Urinary Retention (POUR) of Sugammadex and Neostigmine Groups — 20; 6 Participants

Primary: Change in Pain Disability - Roland Morris Disability Questionnaire (RMDQ) Score — 8.7; 10.1; 6.4 score on a scale

Primary: Normalized Serum Leptin Levels — 96.7; 94.0; 90.0; 101.0 percentage of mean baseline leptin — p=0.22

Primary: Sensitivity of Detecting Solid Organ Injury Measured as the Number of True Positives — 18; 20 Participants

Primary: Number of Participants With Adverse Events (AEs) — 130; 94 Participants

Primary: Number of New COVID 19 Infections — 25; 21 Participants

Primary: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) — 20; 27; 6; 9 Participants

Primary: Successful Reperfusion — 305; 149 Participants — p=0.05

Primary: Comparison of Accuracy of ReSTE Imaging to SPECT Imaging in Diagnosis of Ischemia — 0.1538; 0.2308 proportion of participants

Primary: Number of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52. — 70; 32 Participants — p=<0.0001

Primary: Patient Satisfaction With Validated FACE-Q Aesthetics Survey — 28.0; 24.0; 36.0; 36.0 score on a scale

Primary: Part A: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) for Sugammadex — 13.40; 16.22; 11.50; 14.07 Hour (hr)*ug/mL

Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min

Primary: Change in Mean Number of Days Per Month With Significant Mid-facial Pain or Pressure — -6.0; -5.8 days per month — p=0.96

Primary: Enrollment Rate — 7 Participants